Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why Zogenix Stock Is on Fire Today

TheMotleyFool

0 0

Shares of the small-cap drugmaker Zogenix (NASDAQ: ZGNX) rose by as much as 67% in pre-market trading Wednesday morning. The company's shares are surging higher today in response to a buyout agreement with the Belgian pharmaceutical company UCB.

UCB will reportedly pay $26 in cash per share for Zogenix. In addition, UCB will be on the hook for another $2 per share if Fintepla is approved for Lennox-Gastaut syndrome in the European Union before the end of 2023. The total potential value of this deal is $1.9 billion. The up-front portion of this transaction represents a hefty 66% premium relative to Zogenix's closing price Tuesday afternoon.

Image source: Getty Images.

Source Fool.com

Like: 0

ZGNX

Share